评估糖转移共生对微生物群组成和脂多糖调节的影响：一项双盲、安慰剂对照研究。

Evaluating the Effects of Sugar Shift Symbiotic on Microbiome Composition and LPS Regulation: A Double-Blind, Placebo-Controlled Study.

作者信息

García Gissel, Soto Josanne, Netherland Michael, Hasan Nur A, Buchaca Emilio, Martínez Duniesky, Carlin Martha, de Jesus Cano Raúl

机构信息

Pathology Department, Clinical Hospital "Hermanos Ameijeiras" (HHA), Calle San Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana 10400, Cuba.

Clinical Laboratory Department, Clinical Hospital "Hermanos Ameijeiras" (HHA), Calle San Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana 10400, Cuba.

出版信息

Microorganisms. 2024 Dec 7;12(12):2525. doi: 10.3390/microorganisms12122525.

DOI:10.3390/microorganisms12122525

PMID:39770729

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11678924/

Abstract

(1) Background: This study evaluated the effects of BiotiQuest Sugar Shift, a novel probiotic formulation, for its impact on gut microbiome composition and metabolic health in type 2 diabetes mellitus (T2D). T2D is characterized by chronic inflammation and gut microbiome imbalances, yet the therapeutic potential of targeted probiotics remains underexplored. (2) Methods: In a 12-week randomized, double-blind, placebo-controlled trial, 64 adults with T2D received either Sugar Shift or placebo capsules twice daily. Each dose provided 18 billion CFU of eight GRAS-certified bacterial strains and prebiotics. Clinical samples were analyzed for metabolic markers, and microbiome changes were assessed using 16S rRNA sequencing and metagenomics. (3) Results: Sugar Shift significantly reduced serum lipopolysaccharide (LPS) levels, improved insulin sensitivity (lower HOMA-IR scores), and increased short-chain fatty acid (SCFA)-producing genera, including Bifidobacterium, and . Pro-inflammatory taxa like decreased, with reduced LPS biosynthesis genes and increased SCFA production genes. The ratio emerged as a biomarker of reduced inflammation. (4) Conclusions: These findings demonstrate the potential of Sugar Shift to restore gut homeostasis, reduce inflammation, and improve metabolic health in T2D. Further studies are warranted to explore its long-term efficacy and broader application in metabolic disease management.

摘要

(1) 背景：本研究评估了新型益生菌制剂BiotiQuest Sugar Shift对2型糖尿病（T2D）患者肠道微生物群组成和代谢健康的影响。T2D的特征是慢性炎症和肠道微生物群失衡，但靶向益生菌的治疗潜力仍未得到充分探索。(2) 方法：在一项为期12周的随机、双盲、安慰剂对照试验中，64名成年T2D患者每天两次服用Sugar Shift或安慰剂胶囊。每剂提供180亿CFU的8种GRAS认证的细菌菌株和益生元。对临床样本进行代谢标志物分析，并使用16S rRNA测序和宏基因组学评估微生物群变化。(3) 结果：Sugar Shift显著降低血清脂多糖（LPS）水平，改善胰岛素敏感性（降低HOMA-IR评分），并增加产生短链脂肪酸（SCFA）的菌属，包括双歧杆菌等。像这样的促炎类群减少，LPS生物合成基因减少，SCFA产生基因增加。该比例成为炎症减轻的生物标志物。(4) 结论：这些发现证明了Sugar Shift在恢复T2D患者肠道内环境稳定、减轻炎症和改善代谢健康方面的潜力。有必要进一步研究以探索其长期疗效及其在代谢疾病管理中的更广泛应用。